An Ile-568 to Asn Polymorphism Prevents Normal Trafficking and Function of the Human P2X₇ Receptor∗

James S. Wiley‡§, Lan-Phuong Dao-Ung¶, Changping Li‡, Anne N. Shemon‡, Ben J. Gut‡, Megan L. Smart‡, Stephen J. Fuller‡, Julian A. Barden‡, Steven Petrou§ and Ronald Sluyter‡

From the ‡Department of Medicine, University of Sydney at Nepean Hospital, Penrith, New South Wales 2750, the ¶Department of Physiology, University of Melbourne, Parkville, Victoria 3050, and the §Department of Anatomy and Histology, University of Sydney, Sydney, New South Wales 2006, Australia

The P2X₇ receptor is a ligand-gated channel that is highly expressed on mononuclear cells and that mediates ATP-induced apoptosis of these cells. Wide variations in the function of the P2X₇ receptor have been observed, in part because of a loss-of-function polymorphism that changes Glu-496 to Ala without affecting the surface expression of the receptor on lymphocytes. In this study a second polymorphism (Ile-568 to Asn) has been found in heterozygous dosage in three of 85 normal subjects and in three of 45 patients with chronic lymphocytic leukemia. P2X₇ function was measured by ATP-induced fluxes of Rb⁺, Ba²⁺, and ethidium into various lymphocyte subsets and was decreased to values of −25% of normal. The expression of the P2X₇ receptor on lymphocytes was approximately half that of normal values as measured by the binding of fluorescein-conjugated monoclonal antibody. Transfection experiments showed that P2X₇ carrying the Ile-568 to Asn mutation was non-functional because of the failure of cell surface expression. The differentiation of monocytes to macrophages with interferon-γ up-regulated P2X₇ function in cells heterozygous for the Ile-568 to Asn mutation to a value around 50% of normal. These data identify a second loss-of-function polymorphism within the P2X₇ receptor and show that Ile-568 is critical to the trafficking domain, which we have shown to lie between residues 551 and 581.

The purinergic P2X₇ receptor is a ligand-gated channel, selective for cationic permeants, which has a wide distribution including cells of the immune and hemopoietic system (1, 2). Activation of this receptor by brief exposure to extracellular ATP opens a channel that allows Ca²⁺ and Na⁺ influx and K⁺ efflux and that initiates a cascade of intracellular downstream events. These include the stimulation of phospholipase D (3, 4), the activation of membrane metalloproteases (5–7), and the stimulation of intracellular caspases, which eventually lead to the apoptotic death of the target cell (8, 9). P2X₇ activation also leads to extensive membrane blebbing (10), which is a typical morphological feature of the apoptotic process. P2X₇ receptors have two transmembrane domains with intracellular amino and carboxyl termini, and the P2X₇ receptor differs from other members of the P2X receptor family in having a long carboxyl terminus of 240 amino acids from the inner membrane face (11). This long carboxyl terminus is necessary for the permeability properties of the P2X₇ receptor because truncation of this tail abolishes ATP-induced uptake of the fluorescent dye Yo-Pro-1 (12). P2X₇ has an oligomeric structure in the membrane based on trimeric or larger complexes of identical subunits (13, 14), and there is evidence that P2X₇ interacts with a number of structural and adhesion proteins in a complex at the cell surface (15). Phosphorylation of a tyrosine at amino acid 343 of the P2X₇ primary structure has been proposed as being important for maintaining the full activity of the P2X₇ channel (15).

A number of regulatory domains or motifs have been identified in the intracellular carboxyl tail based on homology with other proteins. These include a potential Src homology 3 binding domain (amino acids 450–456) and an ankyrin repeat motif (amino acids 494–508) (16). Ankyrin repeats have been shown to play a major structural role in protein anchoring to the membrane or cytoskeleton, protein folding, and protein-protein interaction (17, 18). In addition, a lipopolysaccharide (LPS) binding motif with homology to the LPS-binding protein of Escherichia coli (16) has been proposed between amino acids 573 and 590, whereas we have shown that a region within this motif (amino acids 551–581) is necessary for the surface expression of P2X₇ (19). Upstream from this motif we have identified a single nucleotide polymorphism (1513A→C), present in around 20% of the population, which changes Glu to Ala at amino acid 496 and which leads to loss of function of the receptor (20). Surface expression of P2X₇ on lymphocytes was not affected by the Glu-496 to Ala polymorphism, suggesting that the loss of function resulted from impaired protein-protein interactions in the P2X₇ complex at the cell membrane rather than from trafficking to the surface (20). In this study, we report the functional effects of a second polymorphism of the human P2X7 gene (thymine to adenine at position 1729 of cDNA) that is associated with loss of function of the P2X₇ receptor because of failure of its trafficking to the cell surface. This polymorphism changes Ile to Asn at amino acid 568, which localizes this residue as being within a trafficking motif in the carboxyl tail of the receptor.

EXPERIMENTAL PROCEDURES

Materials—ATP, ethidium bromide, BaCl₂, β-D-glucose, bovine serum albumin, RPMI 1640 medium, gentamicin, collagen (Type X), and glyc-

* This work was supported by the National Health and Medical Research Council, the Cure Cancer Australia Foundation, and the Leukaemia Foundation of Australia. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¶ To whom correspondence should be addressed: Level 5, South Block, Nepean Hospital, Penrith, NSW 2750, Australia. Tel.: 61-2-4734-3277; Fax: 61-2-4734-3432; E-mail: wileyj@medicine.usyd.edu.au.

1 The abbreviations used are: LPS, lipopolysaccharide; CLL, chronic lymphocytic leukemia; FITC, fluorescein isothiocyanate; mAb, monoclonal antibody(ies); HEK, human embryonic kidney; NK, natural killer.

17108 This paper is available on line at http://www.jbc.org
erol gelatin mounting medium were purchased from Sigma. Interferon-γ was obtained from Roche Diagnostics. Ficoll-Paque™, fetal calf serum, normal horse serum, LipofectAMINE™ 2000 reagent, Opti-MEM I medium, and Taq DNA polymerase were purchased from Invitrogen. Ficoll-Paque™ and 86RbCl (1.5 mCi/ml; specific radioactivity, 3 Ci/um). For the generation of macrophages, the mononuclear cell preparation was resuspended in HEPES-buffered NaCl medium (145 mM NaCl, 5 mM KCl, 10 mM HEPES, 5 mM glucose, 0.1% bovine serum albumin, pH 7.5) at 37 °C. BaCl2 (1.0 mM) was added and was followed 40 s later by the addition of 1.0 mM ATP (arrow). The mean channel of cell-associated fluorescence intensity was measured at 2-s intervals for gated CD3+/CD16+ T-lymphocytes (top panel) or CD16+ NK cells (bottom panel). Basal Ba2+ influx measured in the absence of ATP is shown (inset). The arbitrary units of the area above the Ba2+ influx curve in the first 20 s after the addition of ATP are 1519 for wild type T-lymphocytes, 720 for heterozygous T-lymphocytes, 2265 for wild type NK cells, and 1038 for heterozygous NK cells. The figure depicts one representative experiment of three performed.

**FIG. 1.** ATP-induced Rb+ efflux from lymphocytes from CLL subjects either wild type or heterozygous for the 1729A allele. Lymphocytes from CLL subjects either wild type at 1729 (△) or heterozygous for the 1729A allele (▲, ▼) were loaded for 2 h with 86Rb+. Cells were washed, resuspended in KCl medium, and incubated for 5 min at 37 °C before incubation with 0.5 mM ATP for 4 min. Samples (1 ml) were collected at 1-min intervals. Basal 86Rb+ efflux measured in the absence of ATP is shown (□). 86Rb+ efflux is expressed as (1 – N/N0), where N0 is the level of cell-associated radioactivity at time t (determined by Cerenkov counting) and N, the amount of cell-associated radioactivity at time 0. The data have been analyzed after log transformation to permit calculation of efflux rate constants. Results from seven different subjects wild type at 1729 are shown as the mean ± S.E. Results from two different subjects heterozygous for the 1729A allele are shown as separate lines (one line being representative of two experiments for each heterozygote subject).

**FIG. 2.** ATP-induced Ba2+ influx into normal human T-lymphocytes and NK cells from subjects either wild type or heterozygous for the 1729A allele. Mononuclear cells from normal subjects either wild type at 1729 (△) or heterozygous for the 1729A allele (▲) were incubated with 1 µg/ml Fura Red for 30 min and washed once. The cells were labeled with FITC-conjugated anti-CD3 or -CD16 mAb and resuspended in KCl medium at 37 °C. Ba2+ (1 mM) was added and was followed 40 s later by the addition of 1 mM ATP (arrow). The mean channel of cell-associated fluorescence intensity was measured at 2-s intervals for gated CD3+/CD16+ T-lymphocytes (top panel) or CD16+ NK cells (bottom panel). Basal Ba2+ influx measured in the absence of ATP is shown (□). The arbitrary units of the area above the Ba2+ influx curve in the first 20 s after the addition of ATP are 1519 for wild type T-lymphocytes, 720 for heterozygous T-lymphocytes, 2265 for wild type NK cells, and 1038 for heterozygous NK cells. The figure depicts one representative experiment of three performed.

**Mechanical scraping for flow cytometric analysis.**

**αRb+ Efflux Measurements**—ATP-induced αRb+ efflux from chronic lymphocytic leukemia (CLL) lymphocytes was performed as described (25).

**β2+ Influx Measurements**—Mononuclear cells (4 × 106) were incubated with Fura Red (1 µg/ml) for 30 min at 37 °C in HEPES-buffered NaCl medium. Cells then were washed once and labeled with appropriate FITC-conjugated anti-CD mAb for 15 min. Cells were washed once and resuspended in 1.0 ml of HEPES-buffered KCl medium (150 mM KCl, 10 mM HEPES, 5 mM glucose, 0.1% bovine serum albumin, pH 7.5) at 37 °C. All samples were stirred and maintained at 37 °C using a Time Zero module (Cytek, Fremont, CA). BaCl2 (1.0 mM) was added and was followed 40 s later by the addition of 1.0 mM ATP. Cells were analyzed at 2000 events/s on a FACSCalibur flow cytometer (BD Biosciences) and were gated by forward and side scatter and by cell type-specific antibodies. The linear mean channel of fluorescence intensity (0–1023 channel) for each gated subpopulation over successive 2-s intervals was analyzed by WinMDI software (Joseph Trotter, version 2.7) and plotted against time.

**Ethidium+ Influx Measurements**—ATP-induced ethidium+ influx into mononuclear cells from normal and CLL subjects and into HEK-293 cells was performed using time-resolved flow cytometry as described (22). Because of the increased P2X7 function on macrophages, data for comparison of ethidium+ uptake between monocytes and macrophages (Fig. 6) were acquired at a reduced voltage setting for FL-2 (ethidium+ fluorescence) as described (7).
Reduced P2X<sub>7</sub> expression and function in leukocytes with the 1729A allele

<table>
<thead>
<tr>
<th>Genotype</th>
<th>P2X&lt;sub&gt;7&lt;/sub&gt; expression (mean channel of fluorescence intensity)</th>
<th>P2X&lt;sub&gt;7&lt;/sub&gt; function (arbitrary units of area under ATP-induced ethidium&lt;sup&gt;+&lt;/sup&gt; uptake curve at 5 min)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>T-lymphocyte</td>
<td>B-lymphocyte</td>
</tr>
<tr>
<td>N1</td>
<td>A/A</td>
<td>T/A</td>
</tr>
<tr>
<td>N2</td>
<td>A/A</td>
<td>T/A</td>
</tr>
<tr>
<td>N3</td>
<td>A/A</td>
<td>T/A</td>
</tr>
<tr>
<td>B-CLL subjects</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CLL1</td>
<td>A/A</td>
<td>T/A</td>
</tr>
<tr>
<td>CLL2</td>
<td>A/A</td>
<td>T/A</td>
</tr>
<tr>
<td>Normal subjects&lt;sup&gt;a&lt;/sup&gt;</td>
<td>A/A</td>
<td>T/T</td>
</tr>
</tbody>
</table>

<sup>a</sup> Mean ± S.E., n = 14–16.

DNA Extraction, Polymerase Chain Reaction, and DNA Sequencing—Genomic DNA was extracted from peripheral blood using the Wizard genomic DNA purification kit (Promega) according to the manufacturer’s instructions. A primer pair was designed within exon 13 of the P2X<sub>7</sub> gene to amplify a 579-bp product from genomic DNA. P2X<sub>7</sub> oligonucleotides were synthesized by Invitrogen. The forward primer was 5′-GAACCTAGAACCTGAGGGCT-3′, and the reverse primer was 5′-GACAGCTGAAGCCACCGTGTC-3′. PCR amplification (32 cycles of denaturation at 95 °C for 30 s, annealing at 56 °C for 30 s, and extension at 72 °C for 1 min) produced a fragment of the expected 579-bp size. Amplified PCR products were purified (GFXTM PCR DNA and gel band purification kit, Amersham Biosciences) and sequenced as described (20).

Site-directed Mutagenesis—Mutated 1729T→A was introduced using overlap PCR (QuikChange<sup>TM</sup> site-directed mutagenesis kit, Stratagene) and the expression vector pCI-SP2X<sub>7</sub>, as described (20). The primer sequences were as follows (base changes are in bold and underlined): T1729A forward, C ATG GCT GAC TTT GCC A and reverse primer was 5′-GACAGCTGAAGCCACCGTGTC-3′. PCR amplification (32 cycles of denaturation at 95 °C for 30 s, annealing at 56 °C for 30 s, and extension at 72 °C for 1 min) produced a fragment of the expected 579-bp size. Amplified PCR products were purified (GFXTM PCR DNA and gel band purification kit, Amersham Biosciences) and sequenced as described (20).

Immunofluorescent Staining and Confocal Microscopy—HEK-293 cells were transfected with wild type or 1729A-mutated P2X<sub>7</sub> cDNA. Non-permeabilized cells (top panels, intracellular P2X<sub>7</sub> expression) and fixed and permeabilized cells (bottom panels, intracellular P2X<sub>7</sub> expression) were labeled with FITC-conjugated anti-P2X<sub>7</sub> mAb (black line) or isotype control mAb (shaded line), and the level of P2X<sub>7</sub> expression was determined by flow cytometry. The figure depicts one representative experiment of three performed.

RESULTS

A Single Nucleotide Polymorphism at Position 1729 of the P2X<sub>7</sub> Gene—A PCR product was amplified directly from genomic DNA to include the whole of exon 13 of the P2X<sub>7</sub> gene, and the product was sequenced. In three of 85 normal subjects, a heterozygous nucleotide substitution (thymine to adenine) was found at position 1729, but no homozygous substitutions were observed. The overall allele frequency of this single nucleotide polymorphism (1729T→A) was 0.04 in the Caucasian population. A comparable allele frequency of 0.06 was found in 45 patients with CLL of whom three were heterozygous for the 1729A allele. The deduced amino acid change for this polymorphism is isoleucine to asparagine at amino acid 568 (I568N) of the P2X<sub>7</sub> protein. All six subjects who were heterozygous for 1729T→A were wild type for the polymorphism that we have described previously at nucleotide 1513 of the P2X<sub>7</sub> gene (20). Subjects identified previously as homozygous for the loss-of-function 1513A→C polymorphism (20) were wild type at position 1729.
ATP-induced \( ^{86}\text{Rb} \) Efflux from Lymphocytes—The function of the P2X7 channel was measured by the ATP-induced efflux of isotopic \( ^{86}\text{Rb} \) from lymphocytes (98% purity) from the peripheral blood of subjects with CLL (25). The lymphocytes were loaded with \( ^{86}\text{Rb} \) in a 2-h preincubation, washed, and incubated at 37°C with or without the addition of 1 mM ATP. In lymphocytes that were wild type for both 1729T and 1513A alleles, the loss of \( ^{86}\text{Rb} \) from the cells over 4 min followed first-order kinetics with a rate constant of 0.03 ± 0.01 min\(^{-1}\) (range of 0.01–0.05, \( n = 7 \)) in the absence of ATP and 0.34 ± 0.04 min\(^{-1}\) (range of 0.24–0.50, \( n = 7 \)) in the presence of ATP (Fig. 1). In two subjects heterozygous for the 1729A allele, the function of the lymphocyte P2X7 channel was either absent or reduced (Fig. 1). In one heterozygote the rate constant for \( ^{86}\text{Rb} \) efflux from lymphocytes was the same in the absence and presence of ATP (0.02 and 0.03 min\(^{-1}\), respectively), whereas in the other heterozygote the addition of ATP increased the rate constant from 0.02 to 0.23 min\(^{-1}\). Data from duplicate experiments for each heterozygote provided in the presence of ATP a mean rate constant of 0.12 ± 0.07 min\(^{-1}\) (\( n = 4 \)), which was significantly lower than the rate constant of 0.34 ± 0.04 min\(^{-1}\) (\( n = 7 \)) for wild type lymphocytes (\( p < 0.01 \), Mann-Whitney \( U \) test). Measurement of isotopic \( ^{86}\text{Rb} \) efflux from lymphocytes of normal subjects was complicated by the variable admixture of monocytes with lymphocytes, and we turned to flow cytometric methods to study P2X7 channel fluxes in defined leukocyte subsets.

P2X7 Expression and Function in Lymphocytes and Monocytes—The permeability of the P2X7 channel was studied by two-color flow cytometry in which the influx of Ba\(^{2+}\) was measured into lymphocytes (either T-lymphocyte or NK cell subsets) identified by appropriate FITC-conjugated mAb. Fig. 2 shows the ATP-induced uptake of Ba\(^{2+}\) into lymphocytes from a normal subject loaded with Fura Red for which fluorescence emission measured by flow cytometry decreases upon the entry of Ba\(^{2+}\) into the cell. The rate of Ba\(^{2+}\) uptake into lymphocytes from this normal subject heterozygous for the 1729A allele was markedly decreased compared with a normal subject who was wild type at this position (Fig. 2). Similar results were observed for the two CLL subjects heterozygous for the 1729A allele (data not shown). A more quantitative estimate of P2X7 receptor channel function was obtained by ATP-induced uptake of a larger permeant, the fluorescent cation ethidium\(^{+}\), for which uptake into lymphocyte and monocyte subsets was measured by time-resolved two-color flow cytometry (22). In three normal subjects who were heterozygous for 1729A, the ATP-induced ethidium\(^{+}\) uptakes were extremely low (only 11–26% of normal mean values (Table I)). The magnitude of the reduction was similar and significant for the three normal cell types studied (T-lymphocytes, \( p < 0.05 \); B-lymphocytes, \( p < 0.01 \); monocytes, \( p < 0.01 \); Mann-Whitney \( U \) test). Surface expression of the P2X7 receptor was measured by the binding of a FITC-conjugated mAb against the extracellular domain of P2X7 (21). P2X7 expression in the three normal subjects heterozygous for the 1729A allele averaged 35 and 50% of the normal mean expression on T- and B-lymphocytes, respectively. Similar results were obtained for lymphocytes and monocytes from two of the subjects with CLL who were heterozygous for the 1729A allele. Both had very low or absent P2X7 function in T-lymphocyte, B-lymphocyte, and monocyte subsets, whereas the surface expression of P2X7 in one heterozygous CLL subject was less than half of the mean value for wild type cells from normal subjects (Table I).

Expression and Function of Ile-568 to Asn-mutated P2X7—cDNA for wild type P2X7 or P2X7, carrying the 1729T→A mutation was transfected into HEK-293 cells, and the expression and function of the receptor were measured. At 40 h after transfection, strong surface expression and function of wild type P2X7 were observed, but the 1729T→A-mutated P2X7 was non-functional using the ATP-induced ethidium\(^{+}\) uptake assay (Fig. 3). The basis for the loss of P2X7 function was failure of trafficking of the mutant receptor to the cell surface shown by the absence of surface P2X7 immunoreactivity in cells transfected with mutated P2X7, and incubated with a mAb to the extracellular domain of P2X7 (Fig. 4). Confocal microscopy confirmed the absence of surface expression of 1729T→A-mutated P2X7, although strong intracellular staining for mutated P2X7 was seen in permeabilized cells (Fig. 5).

Macrophage P2X7 Function—Differentiation of monocytes...
A Polymorphism Prevents P2X7 Trafficking and Function

into macrophages increases the expression and function of P2X7 by manyfold (27). Peripheral blood monocytes were cultured for 7 days (with interferon-γ present for the final 24 h), and the P2X7 function was measured by ATP-induced ethidium uptake into the CD14 macrophage population. Macrophages from a normal subject with wild type P2X7 had an ATP-induced ethidium uptake 10-fold greater than their precursor monocytes (Fig. 6). Thus the area under the ATP-induced ethidium uptake curve increased from 5193 units on day 0 monocytes to 49,314 units on day 7 macrophages. Macrophages from a normal subject heterozygous for the 1729A allele also increased their P2X7 function from 845 units on day 0 monocytes to 26,606 on day 7 macrophages, but this function was only 54% that of macrophages that were wild type with both 1729T and 1513A alleles (Fig. 6).

Discussion

The present study has identified a single nucleotide polymorphism that leads to a loss of function of P2X7, because of a trafficking defect in this receptor. This polymorphism was at position 1729 in the cDNA that changes isoleucine to asparagine at amino acid position 568. Three of 85 normal subjects were found to be heterozygous for this polymorphic variation, and all three had half-normal expression of the P2X7 on the cell surface and reduction of P2X7 function to 25% of normal. Transfection experiments provided confirmation that the Ile-568 to Asn-mutated P2X7 fails to traffic to the cell surface. HEK-293 cells transfected with this mutated P2X7 showed neither surface expression nor function despite plentiful intracellular synthesis of this receptor (Figs. 4 and 5). In other experiments, we measured the physiological properties of the Ile-568 to Asn-mutated P2X7 in Xenopus oocytes and found channel currents in oocytes that were identical to those with the wild type P2X7 construct.2 This result shows that the Ile-568 to Asn mutation does not alter the function of the P2X7 channel, although this result shows differences in trafficking between the mammalian and amphibian expression systems. A number of functional domains have been proposed in the long carboxyl terminus of P2X7 based on protein sequence homology. The most distal of these, the “LPS-binding domain” from amino acids 573 to 590, has homology with the LPS-binding protein of plasma and has been suggested to interact directly with internalized LPS (16). Using a series of truncated mutants of rat P2X7, we have identified previously a region between residues 551 and 581 that is both highly conserved and necessary for the surface expression of this receptor (19). Mutation of the conserved residues at Cys-572, Arg-574, and Phe-581 abolished both cell surface expression and receptor function (19), suggesting that the trafficking domain of P2X7 overlaps the putative LPS-binding domain. The present study adds the conserved Ile-568 to the other residues within this trafficking domain required for cell surface expression of P2X7. Whether this domain binds directly to phospholipid or to one of the many protein partners in the P2X7 membrane complex (15) is uncertain. However, this domain includes a conserved cysteine, palmitoylation of which is required for cell surface expression in a number of other receptors such as CCR5 (28). Recently, P2X7 but not P2X4 receptors have been shown to undergo constitutive endocytosis in neurons (29). Whether P2X7 also undergoes constitutive endocytosis is unknown, but the lack of 1729T→A mutated P2X7 expressed on the surface of HEK-293 cells may be because of the rapid endocytosis of the receptor after initial trafficking to the cell surface. This, however, seems unlikely, as we failed to detect mutant P2X7 on the surface of HEK-293 cells using either flow cytometry or confocal microscopy. Wide variations in the function of the P2X7 receptor have been observed in lymphocytes both from normal subjects (20) and patients with CLL (30). Some but not all of this variability is a result of a single nucleotide polymorphism (1513A→C) that changes Glu-496 to Ala and leads to loss of function without affecting surface expression of the receptor in lymphocytes (20). The trafficking-defective polymorphism identified in the present study, Ile-568 to Asn, contributes to this variability in P2X7 function but with a lower heterozygote prevalence of 4% compared with 20% for the more common Glu-496 to Ala variation. Collectively, however, these two genotypes still do not account for all individuals with low or absent P2X7 function (20, 30). The coding region within exon 13 of the P2X7 gene is highly polymorphic with five single nucleotide polymorphisms identified within a 0.5-kb stretch of cDNA,3 and it is likely that other loss-of-function polymorphisms exist in the P2X7 gene, both within the coding region and in the upstream promoter of this gene (31). Recently a polymorphism affecting the function of the mouse P2X7 receptor has been recognized in inbred strains of mice. Although most strains of mice carried Pro-451 with good P2X7 function, C57BL and DBA strains possessed a Leu-451 allele with lower P2X7 function (32). Whether the recognition or docking sequence around residue 451 lies within a domain interacting with a Src homology 3-binding protein is not known. We have surveyed 99 human base sequences coding for residue 451 but have found no deviations from the wild type sequence.4

An increasing number of channelopathies have been associated with human disease. Thus hypokalemic periodic paralysis and familial hemiplegic migraine result from missense or point mutations in a voltage-sensitive calcium channel (33, 34). Mutations in sodium and potassium channels also can cause neurological disease with ataxic or epileptic phenotypes (34–36). There is increasing interest in channelopathies that affect cells of the immune system and the impact of reduced or absent P2X7 channel function on human susceptibility to infectious diseases. P2X7 receptor expression is up-regulated in macrophages from subjects heterozygous for Asn-568 failed to up-regulate P2X7 function to the same extent as wild type subjects (Fig. 6). Although a mouse strain of P2X7-null genotype has been developed, there is no distinctive adverse phenotype of this animal (40, 41). However, the severity of inflammatory arthritis induced by anti-collagen antibody was markedly attenuated in these animals (41). It seems likely that the P2X7 receptor and its polymorphic variants will be central in our understanding of certain inflammatory and infectious diseases.

Acknowledgments—We thank Dr. Diane Williams for blood collection; Prof. Graeme Stewart, Dr. David Booth, and Maria Ban for helpful discussions; Shelley Spicer for typing this manuscript; and Kristen Skarratt for critically reviewing the manuscript.

References


2 M. L. Smart, unpublished observations.

3 C. Li, R. Suyler, B. J. Gu, and J. S. Wiley, unpublished observations.

4 C. Li and J. S. Wiley, unpublished observations.